0.12
-0.0259(-17.75%)
Currency In USD
Address
2525 East North Carolina Highway 54
Durham, DE 27713
United States of America
Phone
919 313 9633
Website
Sector
Healthcare
Industry
Biotechnology
Employees
218
First IPO Date
December 01, 2020
| Name | Title | Pay | Year Born |
| Laura E. Niklason | Founder, President, Chief Executive Officer & Director | 905,436 | 1963 |
| Shamik J. Parikh | Chief Medical Officer | 514,719 | 1973 |
| Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer & Treasurer | 704,189 | 1960 |
| Heather Connelly | Senior Vice President of Quality | 0 | N/A |
| Yang Cao | Chief Regulatory Officer | 0 | 1966 |
| William John Scheessele | Chief Commercial Officer | 0 | 1972 |
| Lisa Molyneux | Executive Vice President of Enterprise Planning & Analysis | 0 | N/A |
| Sabrina Osborne | Chief People Officer | 0 | N/A |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.